Physician profile
Robert J Schimenti
NPI 1326007428
$3,672.49
in general payments reported to CMS, 2019-2025
24 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $296 · 2021: $308 · 2022: $277 · 2023: $603 · 2024: $406 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $673.97 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $575.26 | 2019-2025 | |
| Boston Scientific Corporation | $368.89 | 2019-2025 | Watchman Flx, Watchman |
| Janssen Pharmaceuticals, INC | $276.11 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $250.80 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.71 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $157.72 | 2019-2020 | |
| Pfizer INC. | $151.41 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $144.34 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $125.98 | 2024-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.29 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $105.73 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $94.29 | 2019-2023 | Farxiga |
| Atricure, INC. | $92.79 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $58.27 | 2019-2023 | Evkeeza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $54.28 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Philips North America LLC | $48.03 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $37.25 | 2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $37.13 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $32.93 | 2025 | Optimizer |
| Avinger INC. | $23.72 | 2022 | |
| Scpharmaceuticals INC. | $23.24 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $15.91 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schimenti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.